Topping-out ceremony at the new Ypsomed site in Schwerin
After completion of the building shell in the coming weeks, the interior work of the production plant will now begin.

Topping-out ceremony at the new Ypsomed site in Schwerin

Press Releases Ypsomed Group

Burgdorf/Schwerin - The topping-out ceremony for Ypsomed's new production plant took place on 28 June 2018. The Swiss medical technology company is building a new production plant in Schwerin's industrial park, creating around 150 new jobs in the region in the coming years. The new production plant will start operations in summer 2019.

Les mer …

Change in the Board of Directors of the Ypsomed Group

Press Releases Ypsomed Group

Burgdorf - On 27 June 2018, the Annual General Meeting of the Ypsomed Group elected Paul Fonteyne as a new member of the Board of Directors and the Compensation Committee of the Ypsomed Group. He is Chairman of Boerhinger Ingelheim USA, and until March 2018 he was President and CEO of Boehringer Ingelheim USA. Paul Fonteyne follows Prof. em. Dr. Norbert Thom, who resigned at the 2018 Annual General Meeting.

Les mer …

Ypsomed significantly increases turnover and invests more in the future

Press Releases Ypsomed Group

Burgdorf – In the business year 2017/18, Ypsomed generated consolidated sales of CHF 466.1 million (prior year: CHF 389.6 million). Compared with the previous year, this represents an increase in sales of 19.7%. The operating results (EBIT) increased by 10.4% compared to the previous year, from CHF 55.3 million to CHF 61.1 million. Net profit increased to CHF 52.1 million (previous year: CHF 46.2 million).

Les mer …

Ypsomed expands to North America

Ypsomed expands to North America

Press Releases Ypsomed Group

Burgdorf – Ypsomed establishes its first subsidiary in North America, Canada. The foundation in Canada is another important milestone in the consistently pursued growth strategy. At the same time, the mylife™ YpsoPump® insulin pump is launched in India.

Les mer …

Ypsomed confirms forecast for the current financial year and looks to the future with confidence

Press Releases Ypsomed Group

Burgdorf - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed expects sustained growth in the Ypsomed Delivery Systems (YDS) segment.

Les mer …